\u3000\u3 Guocheng Mining Co.Ltd(000688) 799 Hunan Warrant Pharmaceutical Co.Ltd(688799) )\u3000
On February 24, 2022, Hunan Warrant Pharmaceutical Co.Ltd(688799) released the annual performance express of 2021. During the reporting period The total operating revenue of the company is about 1.15 billion yuan An increase of 20.6% year on year: the net profit attributable to the owner of the parent company is about 160 million yuan An increase of 10.3% year on year: the net profit attributable to the owner of the parent company after deducting non recurring profits and losses is about 140 million yuan Year on year growth of 11.3%.
The company’s revenue and net profit continued to grow steadily. The increase was mainly due to the increased sales of digestive products such as colloidal pectin bismuth preparation, anti anemia products such as ferrous succinate tablets, anti infection products such as fosfomycin aminobutanol powder, respiratory products such as acetylcysteine solution for inhalation and API products such as mycophenolate mofetil ester.
The market penetration of the company’s core chemical preparations has increased rapidly with good curative effect, low side effects and the company’s strong channel expansion ability. The price of some products has decreased due to the influence of volume purchase However, the product sales volume increased, the sales cost decreased and the company’s cost control ability was strong. Therefore, the policy did not have a great impact on the company’s net profit.
The company’s API business has formed a stable strategic cooperative relationship with a number of pharmaceutical enterprises with high product quality and strong production and R & D capacity, and the business has increased steadily.
